Securities code: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) securities abbreviation: Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) Announcement No.: 2022039 Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266)
About adjusting the company’s issuance to specific objects in 2021
Announcement of A-share stock scheme
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) (hereinafter referred to as “the company”) held the 25th meeting of the first board of directors and the 20th meeting of the first board of supervisors on November 25, 2021, deliberated and adopted the proposal on the company’s plan for issuing A-Shares to specific objects in 2021 and other proposals related to the company’s issue of A-Shares to specific objects in 2021.
The company held the first meeting of the second board of directors and the first meeting of the second board of supervisors on May 19, 2022, The proposal on the company’s plan for issuing A-Shares to specific objects in 2021 (Revised Draft), the proposal on the company’s plan for issuing A-Shares to specific objects in 2021 (Revised Draft), the proposal on the demonstration and analysis report of the company’s plan for issuing A-Shares to specific objects in 2021 (Revised Draft) and other relevant proposals were reviewed and passed. In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of securities issuance and registration of companies listed on the science and Innovation Board (for Trial Implementation) and other relevant laws, regulations and normative documents, the board of directors of the company adjusted the scale and purpose of the raised funds in the issuance plan for issuing A-share tickets to specific objects in 2021. The specific contents are as follows:
Before revision:
The total amount of funds raised in this issuance shall not exceed RMB 286285 million (including this amount). After deducting the issuance expenses, it is proposed to be used for the following items:
Unit: 10000 yuan
No. project name total amount of proposed investment amount of proposed raised funds
1 new drug R & D project 183169183169
2. Phase III construction project of new drug R & D and production center 7258363116
3. Supplementary working capital 40000
Total 295752286285
Within the scope of the above-mentioned projects invested with raised funds, the company can appropriately adjust the investment sequence and specific amount of the corresponding projects invested with raised funds according to the actual situation such as the progress and capital demand of the project. Before the funds raised in this offering are in place, the company can invest with self raised funds according to the actual situation of the investment projects with raised funds, and replace them in accordance with the procedures specified in relevant laws and regulations after the raised funds are in place. After the funds raised in this offering are in place, if the actual net amount of funds raised after deducting the issuance expenses is less than the total amount of funds to be invested, the board of directors and its authorized persons of the company can adjust and finally decide the investment projects, priority and specific investment amount of each project of the raised funds according to the authorization of the general meeting of shareholders, combined with the actual amount of funds raised and the specific situation of project implementation, and the insufficient part shall be solved by the company’s self raised funds.
If the total amount of funds raised in this offering is adjusted due to changes in regulatory policies or the requirements of the issuance registration documents, it will be adjusted accordingly at that time.
Revised:
The total amount of funds raised in this offering does not exceed RMB 145529 million (including this amount). After deducting the issuance expenses, it is proposed to be used for the following items:
Unit: 10000 yuan
No. project name total amount of proposed investment amount of proposed raised funds
1 new drug R & D project 123110123110
2 phase III construction project of new drug R & D and production center 7258322419
Total 195693145529
Within the scope of the above-mentioned projects invested with raised funds, the company can appropriately adjust the investment sequence and specific amount of the corresponding projects invested with raised funds according to the actual situation such as the progress and capital demand of the project. Before the funds raised in this offering are in place, the company can invest with self raised funds according to the actual situation of the investment projects with raised funds, and replace them in accordance with the procedures specified in relevant laws and regulations after the raised funds are in place. After the funds raised in this offering are in place, if the actual net amount of funds raised after deducting the issuance expenses is less than the total amount of funds to be invested, the board of directors and its authorized persons of the company can adjust and finally decide the investment projects, priority and specific investment amount of each project of the raised funds according to the authorization of the general meeting of shareholders, combined with the actual amount of funds raised and the specific situation of project implementation, and the insufficient part shall be solved by the company’s self raised funds.
If the total amount of funds raised in this offering is adjusted due to changes in regulatory policies or the requirements of the issuance registration documents, it will be adjusted accordingly at that time.
In addition to the above adjustments, other contents of the company’s plan to issue A-Shares to specific objects in 2021 remain unchanged.
According to the proposal on requesting the general meeting of shareholders to authorize the board of directors and its authorized persons to fully handle the specific matters of issuing A-Shares to specific objects reviewed and approved by the second extraordinary general meeting of shareholders in 2021, the adjustment of the company’s plan of issuing A-Shares to specific objects in 2021 does not need to be submitted to the general meeting of shareholders for deliberation.
In 2021, the issue of A-Shares to specific objects by the company needs to be reviewed and approved by Shanghai Stock Exchange, and can be implemented only after the China Securities Regulatory Commission makes a decision on approval and registration. The company will perform the obligation of information disclosure in time according to the progress of the matter and in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to the risks.
It is hereby announced.
Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) board of directors may 20, 2022
